CA3171623A1 - Extracellular vesicles for therapy - Google Patents
Extracellular vesicles for therapy Download PDFInfo
- Publication number
- CA3171623A1 CA3171623A1 CA3171623A CA3171623A CA3171623A1 CA 3171623 A1 CA3171623 A1 CA 3171623A1 CA 3171623 A CA3171623 A CA 3171623A CA 3171623 A CA3171623 A CA 3171623A CA 3171623 A1 CA3171623 A1 CA 3171623A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- scaffold
- linked
- moiety
- aspects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2020/024023 | 2020-03-20 | ||
| PCT/US2020/024023 WO2020191361A2 (en) | 2019-03-21 | 2020-03-20 | Extracellular vesicles for vaccine delivery |
| US202063001088P | 2020-03-27 | 2020-03-27 | |
| US63/001,088 | 2020-03-27 | ||
| US202063003171P | 2020-03-31 | 2020-03-31 | |
| US63/003,171 | 2020-03-31 | ||
| US202063006585P | 2020-04-07 | 2020-04-07 | |
| US63/006,585 | 2020-04-07 | ||
| US202063017514P | 2020-04-29 | 2020-04-29 | |
| US63/017,514 | 2020-04-29 | ||
| US202163142418P | 2021-01-27 | 2021-01-27 | |
| US63/142,418 | 2021-01-27 | ||
| PCT/US2021/023485 WO2021189047A2 (en) | 2020-03-20 | 2021-03-22 | Extracellular vesicles for therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3171623A1 true CA3171623A1 (en) | 2021-09-23 |
Family
ID=77771656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3171623A Pending CA3171623A1 (en) | 2020-03-20 | 2021-03-22 | Extracellular vesicles for therapy |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250114445A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4121450A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023518414A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021236763A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3171623A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021189047A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12357704B2 (en) | 2019-05-06 | 2025-07-15 | Thomas Malcolm | Tailored hypoimmune nanovesicular delivery systems for cancer tumors |
| WO2022013609A1 (en) * | 2020-07-13 | 2022-01-20 | Immunovaccine Technologies, Inc. | Sars-cov-2 vaccine compositions and methods of preparation and use |
| WO2023056468A1 (en) * | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
| JP2024537791A (ja) * | 2021-10-01 | 2024-10-16 | グリットストーン バイオ インコーポレイテッド | 汎コロナウイルスワクチン |
| WO2023085821A1 (ko) * | 2021-11-10 | 2023-05-19 | 주식회사 씨케이엑소젠 | 엑소좀 기반 항바이러스 백신 및 이의 제조방법 |
| CA3257248A1 (en) * | 2022-05-25 | 2023-11-30 | Thomas Malcolm | BIOMIMITED HYPOIMMUNE ALLOGENEIC NANOVESICULE FOR CANCER TREATMENT |
| EP4538381A4 (en) * | 2022-07-13 | 2025-10-22 | Univ Ewha Ind Collaboration | EXTRACELLULAR VESICLE COMPRISING AN ANTIGENIC PROTEIN OR A GENE ENCODING THIS PROTEIN, AND USES THEREOF |
| CN120500355A (zh) * | 2022-08-17 | 2025-08-15 | 隆萨销售股份有限公司 | 包含生物活性分子和细胞穿透肽可裂解接头的细胞外囊泡 |
| EP4713015A1 (en) * | 2023-05-17 | 2026-03-25 | National University of Singapore | Surface display of immunotherapeutics on extracellular vesicles and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO2004073319A2 (en) * | 2003-02-14 | 2004-08-26 | Anosys, Inc. | Methods and compounds for raising antibodies and for screening antibody repertoires |
| AU2004254600A1 (en) | 2003-06-26 | 2005-01-13 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US20090169576A1 (en) | 2005-10-26 | 2009-07-02 | Roberto Crea | Influenza combinatorial antigen vaccine |
| EP2510946B1 (en) | 2007-02-07 | 2015-08-05 | The Regents of The University of California | Conjugates of synthetic tlr agonists and uses therefor |
| WO2009026660A1 (en) | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| EP2200639B1 (en) | 2007-09-24 | 2016-03-30 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use |
| US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
| CA2732437C (en) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| EP2486134B1 (en) | 2009-10-06 | 2014-01-08 | Panacela Labs, Inc. | Use of toll-like receptor and agonist for treating cancer |
| KR101866893B1 (ko) | 2010-10-01 | 2018-06-14 | 벤티알엑스 파마슈티칼스 인코포레이티드 | Tlr 아고니스트의 치료적 용도 및 병용 요법 |
| LT2714071T (lt) | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 癌処置としてのstingアゴニストの使用 |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| EP3233191A1 (en) | 2014-12-16 | 2017-10-25 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| US11066453B2 (en) * | 2015-05-18 | 2021-07-20 | Biomvis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| KR20180066241A (ko) | 2015-10-28 | 2018-06-18 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법 |
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| KR20240033086A (ko) | 2017-08-25 | 2024-03-12 | 코디악 바이오사이언시즈, 인크. | 막 단백질을 사용한 치료용 엑소좀의 제조 |
| US20190151456A1 (en) | 2017-11-17 | 2019-05-23 | Codiak Biosciences, Inc. | Compositions of Engineered Exosomes and Methods of Loading Luminal Exosome Payloads |
| EP3731849A4 (en) * | 2017-12-28 | 2021-12-01 | Codiak BioSciences, Inc. | EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY |
| TW202003032A (zh) * | 2018-03-23 | 2020-01-16 | 美商科迪亞克生物科學公司 | 包含s t i n g 促效劑之胞外囊泡 |
| EP4059510B1 (en) | 2018-11-16 | 2025-05-21 | Lonza Sales AG | Engineered extracellular vesicles and uses thereof |
| WO2020191361A2 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicles for vaccine delivery |
-
2021
- 2021-03-22 JP JP2022556038A patent/JP2023518414A/ja active Pending
- 2021-03-22 CA CA3171623A patent/CA3171623A1/en active Pending
- 2021-03-22 WO PCT/US2021/023485 patent/WO2021189047A2/en not_active Ceased
- 2021-03-22 AU AU2021236763A patent/AU2021236763A1/en not_active Abandoned
- 2021-03-22 US US17/906,849 patent/US20250114445A1/en active Pending
- 2021-03-22 EP EP21717740.1A patent/EP4121450A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021236763A1 (en) | 2022-10-06 |
| WO2021189047A3 (en) | 2021-11-04 |
| WO2021189047A2 (en) | 2021-09-23 |
| US20250114445A1 (en) | 2025-04-10 |
| EP4121450A2 (en) | 2023-01-25 |
| JP2023518414A (ja) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11992527B2 (en) | Extracellular vesicles for vaccine delivery | |
| US20250114445A1 (en) | Extracellular vesicles for therapy | |
| TWI846697B (zh) | 工程化細胞外囊泡及其用途 | |
| US20250154218A1 (en) | IL-2 Conjugates and Methods of Use to Treat Autoimmune Diseases | |
| US20240082389A1 (en) | Methods of producing extracellular vesicles | |
| US20230114434A1 (en) | Extracellular vesicles for treating neurological disorders | |
| US20230181758A1 (en) | Extracellular vesicles targeting dendritic cells and uses thereof | |
| CN114072157A (zh) | 工程化的嵌合融合蛋白组合物及其使用方法 | |
| JP7507090B2 (ja) | 免疫腫瘍及び抗炎症療法のためのエクソソーム | |
| US20220251200A1 (en) | Extracellular vesicles targeting t cells and uses thereof | |
| TW202003032A (zh) | 包含s t i n g 促效劑之胞外囊泡 | |
| JP2022519275A (ja) | エクソソーム操作のための膜タンパク質足場 | |
| Huang | Drug design strategies for modulating immune activity for the treatment of autoimmune diseases and cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S) Effective date: 20240903 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250225 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250625 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251110 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260504 |